{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:40:21Z","timestamp":1794274821965,"version":"4.9.0"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T00:00:00Z","timestamp":1442188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007827","name":"American College of Gastroenterology","doi-asserted-by":"crossref","award":["Faculty Development Grant"],"award-info":[{"award-number":["Faculty Development Grant"]}],"id":[{"id":"10.13039\/100007827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background &amp; Aims<\/jats:title><jats:p>Prednisolone is the first\u2010line therapy for severe alcoholic hepatitis (<jats:styled-content style=\"fixed-case\">AH<\/jats:styled-content>). Patients with severe alcoholic hepatitis often develop severe infections that negatively impact short\u2010term prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed this meta\u2010analysis to assess the effect of corticosteroids on the occurrence of and mortality from infections in patients with severe alcoholic hepatitis. Randomized controlled trials examining the use of corticosteroids in severe alcoholic hepatitis and reporting data on infection rates and mortality were included. Random effects model was used to pool the data comparing arms with and without steroids for the occurrence of infection, 28\u2010day mortality and cause specific mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1062 patients (528 steroids treated) without infection at baseline from 12 studies, infection was reported in 213 (113 steroids treated) patients without differences comparing arms with and without steroids (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>: 0.98; <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.49\u20131.94). However, frequency was higher for occurrence of fungal infections among steroid\u2010treated patients (eight of 528 vs. one of 534; <jats:italic>P<\/jats:italic> = 0.02). Steroids provided mortality benefit at 28 days (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>: 0.55; <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.34\u20130.90) mainly for liver failure\u2010related death (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>: 0.46; <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.24\u20130.87) without differences on mortality from infection (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>: 1.19; <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.38\u20133.73) or gastrointestinal bleeding (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>: 0.90; <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.43\u20131.87). Three of nine patients with fungal infections died, all in corticosteroid arm.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Corticosteroids do not increase occurrence of or mortality from bacterial infections in patients with severe alcoholic hepatitis. Further studies are needed to develop strategies of reducing the risk of fungal infection with use of steroids for patients with severe alcoholic hepatitis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.12939","type":"journal-article","created":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T07:07:43Z","timestamp":1439795263000},"page":"721-728","source":"Crossref","is-referenced-by-count":79,"title":["Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta\u2010analysis of randomized trials"],"prefix":"10.1111","volume":"36","author":[{"given":"Bashar S.","family":"Hmoud","sequence":"first","affiliation":[{"name":"Department of Internal Medicine University of Texas Medical Branch Galveston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kershaw","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of Chicago Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology University of North Carolina Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani K.","family":"Singal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology University of Alabama Birmingham AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.06.013"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0805786"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-74-3-311"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197106172842404"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200412000-00023"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-79-5-625"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-9-685"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0016-5085(80)90867-7","article-title":"Double\u2010blind controlled trial of prednisolone therapy in patients with severe","volume":"78","author":"Depew W","year":"1980","journal-title":"Gastroenterology"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(78)90401-8"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8964410"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112302"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260802"},{"key":"e_1_2_8_14_1","first-page":"443","article-title":"A controlled trial of 6\u2010methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients","volume":"69","author":"Shumaker JB","year":"1978","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.8627"},{"issue":"1","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0016-5085(78)90790-4","article-title":"Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements","volume":"74","author":"Lesesne HR","year":"1978","journal-title":"Gastroenterology"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.23.1.75"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01072499"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00289-6"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412278"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23258"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.04.004"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.04.062"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27779"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/11.6.954"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v4.i2.16"},{"key":"e_1_2_8_27_1","first-page":"612A","volume-title":"Hepatology","author":"Ahn J","year":"2009"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.039"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1321.009"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32835d83d9"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2939"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.09.011"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105703"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20140101"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12939","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:22:26Z","timestamp":1695547346000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,14]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/liv.12939"],"URL":"https:\/\/doi.org\/10.1111\/liv.12939","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,14]]}}}